Radium Ra 223 dichloride (Xofigo®) in Castrate-Resistant Prostate Cancer (CRPC)

This PQI in Action is a follow up to the Radium Ra 223 Dichloride (Xofigo) Management PQI and explores how the medically integrated teams at First Urology and Comprehensive Cancer Centers of Nevada (CCCN) collaborate and utilize the information found in the PQI as part of their daily practice. This PQI in Action focuses on the use of radium-223 in patients with CRPC.